Cardiovascular Biotech Celyad Targets $115M In US IPO
Celyad SA laid the groundwork Monday to access the U.S. public market, filing with regulators to raise $115 million in an initial public offering and a concurrent private offering as the...To view the full article, register now.
Already a subscriber? Click here to view full article